Bispecifics in R/R MM: AE Management and Sequencing

Panelist discusses how every drug oncologists use comes with adverse events (AEs), and with bispecifics they are seeing a similar AE profile to that seen in CAR T-cell therapy. There are 3 major AEs: cytokine release syndrome, neurological toxicity, and infections. To manage AEs, oncologists are now monitoring patients more intensely as well as engaging with the patient’s family to provide updates on the status of the patient.

EP: 1.R/R MM: Treating Patients with CNS Metastases Involvement

EP: 2.Optimal Dosing Strategies and Managing AEs

EP: 3.R/R MM: Bispecifics in R/R MM: Key Takeaways

EP: 4.R/R MM: Insights Into Optimal Dosing for Bispecifics

Now Viewing

EP: 5.Bispecifics in R/R MM: AE Management and Sequencing

EP: 6.Future Perspectives in R/R MM

EP: 7.R/R MM Treatment Landscape: Role of Bispecifics

EP: 8.Clinical Pearls Surrounding the Use of Bispecifics in R/R MM

Video content above is prompted by the following

• What AEs are you seeing in practice with bispecifics?
• What are some strategies used to manage them?
• What is your current approach to sequencing bispecifics (BCMA vs non-BCMA bispecific, CAR T vs bispecifics)?
• What insights can you share for fellow oncologists regarding sequencing?

Recent Videos